Clinical Trial Detail

NCT ID NCT01436656
Title A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

colorectal cancer

Therapies

Encorafenib

Age Groups: senior adult

Additional content available in CKB BOOST